Frontiers in Oncology | Cancer Immunity and Immunotherapy

Case Report

Published on 31 Oct 2025

Case Report: IL-6 suppression: a potential strategy for mitigating severe immune-related adverse events in nivolumab and ipilimumab therapy for malignant pleural mesothelioma

in Cancer Immunity and Immunotherapy

Asako Yanagisawa
Takumi Fukaya
Kento Noda
Hiroshi Kojima
Hidefumi Shimizu

Frontiers in Oncology

doi 10.3389/fonc.2025.1671503

192 views

Mini Review

Published on 31 Oct 2025

Decoding the immune microenvironment in osteosarcoma: new insights into checkpoints, vaccines, and CAR-T cells

in Cancer Immunity and Immunotherapy

Haitian Wang
Tongtong Zhu
Kunpeng Yang
Chenkai Xu
Zhaoyi Zhang
Guangyao Liu
Hongge Ren

Frontiers in Oncology

doi 10.3389/fonc.2025.1702219

116 views

Original Research

Published on 30 Oct 2025

Dual oncogenic role of RNF220 in AML: linking metabolic rewiring to cell proliferation and immune evasion

in Cancer Immunity and Immunotherapy

Bixia Li
Shi Jiang
Yao Xu
Xiao Yan
Qitian Mu
Guifang Ouyang

Frontiers in Oncology

doi 10.3389/fonc.2025.1670895

144 views

Original Research

Accepted on 29 Oct 2025

First-line Immune Checkpoint Inhibitors Combined with Chemotherapy in Advanced Large-cell Neuroendocrine Carcinoma of the Lung: A Real-world Retrospective Study

in Cancer Immunity and Immunotherapy

Beibei Ji
Wei Luan
Rula Sha
Wenxin Li

Frontiers in Oncology

124 views

Systematic Review

Published on 29 Oct 2025

Navigating the risks: a systematic review of immune checkpoint inhibitor therapy before liver transplant for hepatocellular carcinoma and its impact on allograft rejection and survival outcomes

in Cancer Immunity and Immunotherapy

Donghua Liu
Xinyi Wang
Xuelian Liu
Jing Li

Frontiers in Oncology

doi 10.3389/fonc.2025.1689820

388 views

Review

Published on 29 Oct 2025

Antibody–drug conjugate: a newly developed biological missile for tumor treatment

in Cancer Immunity and Immunotherapy

Zhuoran Tang
Yanchun Xie
Yanping Zeng

Frontiers in Oncology

doi 10.3389/fonc.2025.1688057

617 views

Original Research

Accepted on 28 Oct 2025

Association Between Immune-Related Adverse Events and Recurrence Dynamics Under Adjuvant Anti– PD-1 Therapy in Resected Melanoma

in Cancer Immunity and Immunotherapy

Gökhan Şahin
CANER ACAR
Haydar Çağatay Yüksel
Salih Tünbekici
Pınar Açar
Banu Yaman
Burcak Karaca

Frontiers in Oncology

112 views

Original Research

Accepted on 28 Oct 2025

Phytochemical and Nanoparticle-Based Therapeutic Potential of Sphaeranthus indicus Against Hepatocellular Carcinoma via Cryptomeridiol Targeting

in Cancer Immunity and Immunotherapy

Ritika Ravindra Konduskar
Abhinandan Patil
Somnath Bhinge
Gourav Rameshlal Chawla
Yash B. Yadav

Frontiers in Oncology

Original Research

Accepted on 28 Oct 2025

Early C-Reactive Protein Reduction Predicts Survival in Real-World Extensive-Stage Small Cell Lung Cancer Treated with First-Line Adebrelimab-Based Immunotherapy

in Cancer Immunity and Immunotherapy

Jian Wang
Xueli Zhang
Qijia Gao
Jianxin Chen

Frontiers in Oncology

Case Report

Accepted on 28 Oct 2025

Accelerated Parathyroid Adenoma Progression and Hypercalcemia-Driven Neurotoxicity Following Pembrolizumab-Based Neoadjuvant Therapy in Triple-Negative Breast Canc er: A Case of Multisystem Immune-Related Adverse Events

in Cancer Immunity and Immunotherapy

Yi Zeng
Yu Sun
Pengfei Qian

Frontiers in Oncology

Case Report

Published on 28 Oct 2025

Immune-related osteitis mimicking femoral head osteonecrosis during dual checkpoint blockade: a case report

in Cancer Immunity and Immunotherapy

Enrica Teresa Tanda
Agostina Lagodin D’Amato
Giovanni Rossi
Maria Maddalena Latocca
Andrea Boutros
Andrea Zanirato
Matteo Formica
Silvia Bozzano
Bruno Spina
Francesco Spagnolo

Frontiers in Oncology

doi 10.3389/fonc.2025.1621774

370 views

Mini Review

Published on 28 Oct 2025

Integrated molecular and microenvironmental drivers of drug resistance in gastrointestinal cancers: mechanisms, immunotherapy challenges, and precision strategies

in Cancer Immunity and Immunotherapy

Heng Xu
Jiaan Lu
Jiangying Wu
Kangling Zhang
Xuancheng Zhou
Ziqi Gao
Jingqi Feng
Ziye Zhuang
Xiaolin Zhong

Frontiers in Oncology

doi 10.3389/fonc.2025.1675745

323 views

Original Research

Accepted on 24 Oct 2025

Adjuvant tyrosine kinase inhibitors plus anti‑PD‑1 therapy reduce recurrence in high-risk hepatocellular carcinoma after resection

in Cancer Immunity and Immunotherapy

Jiaxin Li
Yukun Sun
Ziniu Liu
Jianwen Huang
Jian Wu
Yun Huang
Yali Gao
Baomin Chen
Qiang He

Frontiers in Oncology

1,020 views

Systematic Review

Published on 24 Oct 2025

The effect of Traditional Chinese Medicine on patients undergoing targeted therapy for primary liver cancer: a systematic review and meta-analysis

in Cancer Immunity and Immunotherapy

Hongting Yan
Yingjie Li
Bin Guo
Bing Yang
Dongxin Tang

Frontiers in Oncology

doi 10.3389/fonc.2025.1674965

721 views

Case Report

Published on 24 Oct 2025

Case Report: Dual checkpoint inhibition with bevacizumab yields dramatic response in synchronous double primary HCC and ICC with lung metastasis

in Cancer Immunity and Immunotherapy

Yu-cheng He
Xin-ye Dai
Ying-hao Lv
Xiao-juan Yang
Qing-yun Xie
Si-nan Xie
Yun-shi Cai
Feng-wei Gao
Tian Lan

Frontiers in Oncology

doi 10.3389/fonc.2025.1670818

373 views

Original Research

Accepted on 23 Oct 2025

Sintilimab plus a Bevacizumab biosimilar (IBI305) in Advanced HCC with Child-Pugh A/B liver function: A Real-World Multicenter Retrospective Study

in Cancer Immunity and Immunotherapy

Yuanxu Zhang
Youhan Miao
Wei Sun
Yixing Yu
Jinjing Wang
Shuang Xiao
Shengwei Lu
Xia Wang
Zhao Weifeng
Yang Li

Frontiers in Oncology

390 views